| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
Herpes virus entry mediator (HVEM) also known as TNFR superfamily 14 (TNFRSF14) is known to regulate immune response in immunity of infection, transplantation and tumor. However expression of HVEM in human cancer has not been well studied. This study aimed to clarify clinical importance of HVEM in human hepatocellular carcinoma.We studied HVEM expression in 150 HCC patients to explore its clinical relevance, prognostic value, and tumor infiltrating Tcells. High HVEM expression was significantly correlated with vascular invasion, PIVKA-II level, and TNM Stage.And it was inversely correlated with tumor-infiltrating CD4, CD8 and CD45RO lymphocytes and expression of perforin, granzyme B, IFN in HCC. More importantly, the HVEM status was identified as an independent prognostic factor. Conclusion: HVEM expression in HCC induces malfunction of TILs and tumor immunity. Therefore, HVEM may be a new therapeutic target for human hepatocellular carcinoma.
|
